28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Genetics of low spinal muscular atrophy carrier frequency in sub‐Saharan Africa

      research-article
      , MD 1 , 2 , , MSc 3 , , MD 4 , , BS 1 , , BA 1 , , MSc, PhD 5 , , PhD 6 , , MSc, CGC 1 , , PharmD, PhD 4 , , MSc, PhD 4 , , MS 1 , , MD 6 , , MD 7 , , PhD 1 , , MD 1 , , MS 8 , , MD 8 , , BA 1 , , MD 4 , , PhD 1 , 9 , , PharmD 4 , , MD 4 , , MD 4 , , PharmD, PhD 10 , , PhD 11 , , PhD 12 , , MD, PhD 5 , , MD, PhD 5 , , PhD 13 , , MD 14 , , PhD 12 , , MD, PhD 4 , 7 , , MD, PhD 15 , , PhD 1 , , PhD 3 , , MD 1 ,
      Annals of Neurology
      Wiley-Liss

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Spinal muscular atrophy (SMA) is one of the most common severe hereditary diseases of infancy and early childhood in North America, Europe, and Asia. SMA is usually caused by deletions of the survival motor neuron 1 ( SMN1) gene. A closely related gene, SMN2, modifies the disease severity. SMA carriers have only 1 copy of SMN1 and are relatively common (1 in 30–50) in populations of European and Asian descent. SMN copy numbers and SMA carrier frequencies have not been reliably estimated in Malians and other sub‐Saharan Africans.

          Methods

          We used a quantitative polymerase chain reaction assay to determine SMN1 and SMN2 copy numbers in 628 Malians, 120 Nigerians, and 120 Kenyans. We also explored possible mechanisms for SMN1 and SMN2 copy number differences in Malians, and investigated their effects on SMN mRNA and protein levels.

          Results

          The SMA carrier frequency in Malians is 1 in 209, lower than in Eurasians. Malians and other sub‐Saharan Africans are more likely to have ≥3 copies of SMN1 than Eurasians, and more likely to lack SMN2 than Europeans. There was no evidence of gene conversion, gene locus duplication, or natural selection from malaria resistance to account for the higher SMN1 copy numbers in Malians. High SMN1 copy numbers were not associated with increased SMN mRNA or protein levels in human cell lines.

          Interpretation

          SMA carrier frequencies are much lower in sub‐Saharan Africans than in Eurasians. This finding is important to consider in SMA genetic counseling in individuals with black African ancestry. Ann Neurol 2014;75:525–532

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype.

          Autosomal recessive spinal muscular atrophy (SMA) is classified, on the basis of age at onset and severity, into three types: type I, severe; type II, intermediate; and type III, mild. The critical region in 5q13 contains an inverted repeat harboring several genes, including the survival motor neuron (SMN) gene, the neuronal apoptosis inhibitory protein (NAIP) gene, and the p44 gene, which encodes a transcription-factor subunit. Deletion of NAIP and p44 is observed more often in severe SMA, but there is no evidence that these genes play a role in the pathology of the disease. In > 90% of all SMA patients, exons 7 and 8 of the telomeric SMN gene (SMNtel) are not detectable, and this is also observed in some normal siblings and parents. Point mutations and gene conversions in SMNtel suggest that it plays a major role in the disease. To define a correlation between genotype and phenotype, we mapped deletions, using pulsed-field gel electrophoresis. Surprisingly, our data show that mutations in SMA types II and III, previously classed as deletions, are in fact due to gene-conversion events in which SMNtel is replaced by its centromeric counterpart, SMNcen. This results in a greater number of SMNcen copies in type II and type III patients compared with type I patients and enables a genotype/phenotype correlation to be made. We also demonstrate individual DNA-content variations of several hundred kilobases, even in a relatively isolated population from Finland. This explains why no consensus map of this region has been produced. This DNA variation may be due to a midisatellite repeat array, which would promote the observed high deletion and gene-conversion rate.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Differences in SMN1 allele frequencies among ethnic groups within North America

            Background: Spinal muscular atrophy (SMA) is the most common inherited lethal disease of children. Various genetic deletions involving the bi-allelic loss of SMN1 exon 7 are reported to account for 94% of affected individuals. Published literature places the carrier frequency for SMN1 mutations between 1 in 25 and 1 in 50 in the general population. Although SMA is considered to be a pan-ethnic disease, carrier frequencies for many ethnicities, including most ethnic groups in North America, are unknown. Objectives and methods: To provide an accurate assessment of SMN1 mutation carrier frequencies in African American, Ashkenazi Jewish, Asian, Caucasian, and Hispanic populations, more than 1000 specimens in each ethnic group were tested using a clinically validated, quantitative real-time polymerase chain reaction (PCR) assay that measures exon 7 copy number. Results: The observed one-copy genotype frequency was 1 in 37 (2.7%) in Caucasian, 1 in 46 (2.2%) in Ashkenazi Jew, 1 in 56 (1.8%) in Asian, 1 in 91 (1.1%) in African American, and 1 in 125 (0.8%) in Hispanic specimens. Additionally, an unusually high frequency of alleles with multiple copies of SMN1 was identified in the African American group (27% compared to 3.3–8.1%). This latter finding has clinical implications for providing accurate adjusted genetic risk assessments to the African American population. Conclusions: Differences in the frequency of SMA carriers were significant among several ethnic groups. This study provides an accurate assessment of allele frequencies and estimates of adjusted genetic risk that were previously unavailable to clinicians and patients considering testing.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations.

              Most spinal muscular atrophy patients lack both copies of SMN1. Loss of SMN1 ('0-copy alleles') can occur by gene deletion or SMN1-to-SMN2 gene conversion. Despite worldwide efforts to map the segmental duplications within the SMN region, most assemblies do not correctly delineate these genes. A near pericentromeric location provides impetus for the strong evidence that SMN1 and SMN2 arose from a primate-specific paralogous gene duplication. Here we meta-analyzed our recent laboratory results together with available published data, in order to calculate new mutation rates and allele/haplotype frequencies in this recalcitrant and highly unstable region of the human genome. Based on our tested assumption of compliance with Hardy-Weinberg equilibrium, we conclude that the SMN1 allele frequencies are: '0-copy disease alleles,' 0.013; '1-copy normal alleles,' 0.95; '2-copy normal alleles (ie, two copies of SMN1 on one chromosome),' 0.038; and '1(D) disease alleles (SMN1 with a small intragenic mutation),' 0.00024. The SMN1 haplotype ['(SMN1 copy number)-(SMN2 copy number)'] frequencies are: '0-0,' 0.00048; '0-1,' 0.0086; '0-2,' 0.0042; '1-0,' 0.27; '1-1,' 0.66; '1-2,' 0.015; '2-0,' 0.027; and '2-1,' 0.012. Paternal and maternal de novo mutation rates are 2.1 x 10(-4) and 4.2 x 10(-5), respectively. Our data provide the basis for the most accurate genetic risk calculations, as well as new insights on the evolution of the SMN region, with evidence that nucleotide position 840 (where a transition 840C>T functionally distinguishes SMN2 from SMN1) constitutes a mutation hotspot. Our data also suggest selection of the 1-1 haplotype and the presence of rare chromosomes with three copies of SMN1.
                Bookmark

                Author and article information

                Journal
                Ann Neurol
                Ann. Neurol
                10.1002/(ISSN)1531-8249
                ANA
                Annals of Neurology
                Wiley-Liss
                0364-5134
                1531-8249
                02 April 2014
                05 May 2014
                : 75
                : 4 ( doiID: 10.1002/ana.v75.4 )
                : 525-532
                Affiliations
                [ 1 ] Neurogenetics Branch, National Institute of Neurological Disorders and StrokeNIH Bethesda MD
                [ 2 ] Institute of Biomedical SciencesGeorge Washington University Washington DC
                [ 3 ] Integrated GeneticsLaboratory Corporation of America Westborough MA
                [ 4 ] Faculty of Medicine and OdontostomatologyUniversity of Bamako BamakoMali
                [ 5 ] Laboratory of Human Cytogenetics, Molecular Genetics, and Reproductive BiologyFarhat Hached University Hospital SousseTunisia
                [ 6 ] Laboratory of Cytogenetics and Microscopy Core, National Human Genome Research InstituteNIH Bethesda MD
                [ 7 ] Neurology ServiceUniversity Hospital Center of Point G BamakoMali
                [ 8 ] National Heart, Lung, and Blood InstituteNIH Bethesda MD
                [ 9 ] National Institute of Nursing ResearchNIH Bethesda MD
                [ 10 ] Faculty of PharmacyUniversity of Bamako BamakoMali
                [ 11 ] Biostatistics Research Branch, National Institute of Allergy and Infectious DiseasesNIH Bethesda MD
                [ 12 ] Clinical Neuroscience Program, National Institute of Neurological Disorders and StrokeNIH Bethesda MD
                [ 13 ] Laboratory of Neurogenetics, National Institute on AgingNIH Bethesda MD
                [ 14 ]University Hospital Center of Gabriel Toure BamakoMali
                [ 15 ] Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases NIH Bethesda MD
                Author notes
                [*] [* ]Address correspondence to Dr Fischbeck, Neurogenetics Branch, NINDS, NIH, 35‐2A1000, 35 Convent Drive, Bethesda, MD 20892‐3705. E‐mail: kf@ 123456ninds.nih.gov
                Article
                ANA24114
                10.1002/ana.24114
                4112719
                24515897
                a390c64d-0501-45e4-ba63-5dddbdcff802
                © 2014 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs 4.0 License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 18 December 2013
                : 27 January 2014
                : 30 January 2014
                Page count
                Pages: 8
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                ana24114
                April 2014
                Converter:WILEY_ML3GV2_TO_NLM version:4.0.5 mode:remove_FC converted:20.05.2014

                Neurology
                Neurology

                Comments

                Comment on this article